TCR deal fren­zy con­tin­ues as blue­bird antes up $30M for new Grit­stone al­liance

Blue­bird bio $BLUE is jump­ing on the AI tar­get-iden­ti­fi­ca­tion plat­form de­vel­oped at the neo-anti­gen biotech Grit­stone to iden­ti­fy some new TCR pro­grams for the pipeline.

TCRs have been all the rage re­cent­ly as biotech fol­lows a tech trail that they be­lieve will lead to a wider range of can­cer drug tar­gets to go af­ter — par­tic­u­lar­ly in sol­id tu­mors, where cell ther­a­pies face some of their biggest chal­lenges. Just days ago blue­bird aligned on a T cell re­cep­tor de­vel­op­ment deal with biotech pow­er­house Re­gen­eron, bag­ging $100 mil­lion for a 50/50 pact on ac­cel­er­at­ing new pro­grams.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.